SIGA Technologies, Inc.
SIGA · Price history
Price at last available close
$3.15
−$0.29 (-8.58%) 1M
2026-10-29
Tap or drag sideways to inspect a price. Use two fingers to compare automatically. Release to scroll. Use Shift + arrow keys to compare with a keyboard.
Company & revenue
About SIGA Technologies, Inc.
Primary reporting period: 2025-12-31 · Research updated Oct 12, 2026. A research update is not a new financial filing.
Who they are
SIGA Technologies, Inc. is a pharmaceutical company with commercialized products, specializing in the health security and infectious disease sectors across the United States. A core offering is TPOXX, an oral antiviral drug formulated to combat human smallpox, a condition caused by the variola virus. Furthermore, the company has forged a strategic collaboration with Cipla Therapeutics.
How they make money
SIGA Technologies is a commercial-stage pharmaceutical company that generates revenue primarily by selling its lead product, TPOXX (tecovirimat), to the U.S. government and international government entities. The company also secures funding through government contracts for development activities and research related to its antiviral product portfolio.
Products & services
The company's primary product is TPOXX (tecovirimat), an antiviral medication used for the treatment of orthopoxvirus infections, including smallpox and mpox.
Brands & revenue mix
Lead antiviral product for the treatment of orthopoxvirus infections.
Separate brand revenue is not available in this research.Source
Revenue share is not unit sales or a best-seller ranking. Parent brands and included sub-brands can overlap; do not add overlapping rows.
Product / operating segments
Period ended 2025-12-31Source
Period ended 2025-12-31Source
Calculated from reported segment revenue. Check the source period and revenue basis before comparing shares. Categories can overlap and may not add to 100%.
Geographic revenue
No reconciled geographic revenue breakdown was confirmed for the current research period.
Customer types
Disclosed major customers
- U.S. Government (BARDA)Source
Customer concentration
The company is highly dependent on U.S. government contracts, specifically with BARDA, for the majority of its revenue as of the fiscal year ended December 31, 2025.
Suppliers, materials & equipment
- Third-party manufacturers — The company relies on third-party manufacturers for the production of TPOXX; specific supplier names are not disclosed.Source
Strengths
- Established long-term supply contracts with the U.S. governmentSource
Financial risk observations and what to check
These are saved observations about business performance, not predictions. Review the company filings alongside the interpretation below. Latest stored financial period end: 2026-06-30.
Opportunity Score is currently unavailable; Wall Street Score remains independently validated.
The unavailable Opportunity Score is a separate model output. It must not be substituted with zero or inferred from the company score.
Quarterly revenue fell 49.5% versus the same quarter last year.
Check comparable business scope and currency, then separate volume, pricing and divestitures. One weaker quarter does not establish that the same decline will continue.
Quarterly EPS fell 65.3% versus the same quarter last year.
Review net income and weighted-average shares together. Per-share earnings can change because of operating performance, nonrecurring items or the share denominator.
Wall Street Score
Overall investment score · Quality, value, risk and opportunity
32
Poor
View category scores →
Company Quality
How good is the actual business—regardless of today’s stock price?
44
Weak
Financial Strength
60
Business Quality / Moat
22
Management
60
Growth Quality
0
Risk / Durability
84
Uses financial strength, moat, management, growth quality and durability. It excludes share price, P/E, market cap, intrinsic value and margin of safety.
Model Outlook
12-month model · What does the model think happens next?
Outperformance analysis is not currently available.
WSS View
The quick read
The overall Wall Street Score is low across its combined quality, valuation and risk inputs. This can reflect an expensive share price, business weaknesses, or both; check Company Quality and the category breakdown before drawing a conclusion.
A current Opportunity Score is not available.
The 12-month model outlook is not currently available.
- •Recent buyback activity is present
- •Valuation is a weaker part of the current profile
- •Revenue fundamentals are weak
- •Asset quality is a weaker factor
Company-specific research
Questions worth answering for SIGA
These questions are generated from this company's current financial and score data so the page adds context instead of treating the headline score as a stand-alone conclusion.
- •What is driving SIGA's revenue decline, and does the latest company filing suggest the weakness is temporary or structural?
- •Is SIGA's positive free cash flow repeatable, or is the current level being helped by temporary working-capital or spending changes?
- •How is SIGA likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
- •What specifically needs to improve for SIGA to reach sustainable profitability?
- •What future growth or profitability would be needed to justify SIGA's current valuation?
Essential Investment Snapshot
Wall Street Score
32
Market Cap
$226.0M
P/E Ratio
-72.7
EPS
$-0.04
52-Week High
$8.55
52-Week Low
$2.83
Beta
0.96
Shares Outstanding
71.6M
Total Revenue
$53.7M
Total Debt
$439K
Dividend
No current dividend
Liquidation Value / Share
$2.31
Momentum & Volatility Signals
Two different market-behavior signals. Momentum measures direction and trend strength. Volatility measures how large and unstable the price moves are, regardless of direction.
Weakening momentum
Low movement
A high momentum score means price has been trending upward with confirming short- and medium-term strength. A low score means downward or weakening momentum.
A high volatility score means larger, less stable price swings. It can happen while a stock is rising or falling, so high volatility is not automatically bullish or bearish.
Important: the volatility score above is based on realized price volatility. Implied volatility (IV) comes from options prices and represents the market's expected future movement. Wall Street Score will keep IV separate and will only display it when a verified options-chain feed is available.
Notices for SIGA
Detected from reported data — verify before acting.Historical repurchase activity
Reported cash flows or share-count measures indicate past repurchase activity. This does not verify an active buyback authorization or future purchases.
Community Sentiment
0 active · 0 total callsNo personal call yet on SIGA.
Potential upside factors
- +Growth opportunities may come from revenue expansion, margin improvement, new products, market-share gains, and stronger cash flow.
- +Established long-term supply contracts with the U.S. government.
- +Positive free cash flow may provide capacity to invest in growth.
Potential downside factors
- −Key risks may include competition, margin pressure, debt levels, valuation risk, and changes in demand within the Drug Manufacturers - Specialty & Generic industry.
- −Dependence on U.S. government appropriations and contract renewals.
- −Reliance on third-party manufacturers for product supply.
- −Regulatory approval risks for additional indications.
These research factors come from saved company research and financial data, not community votes. They are starting points to verify against filings, not buy or sell recommendations.
Create a free account to make a call.
Scores
Click any score for full breakdownWas this stock page easy to understand?
One click helps us improve the research experience. This is not tied to an investment decision.
Score Changes
3 historical score records availablePrevious Score
32
Oct 1, 2026
Change
+0.2
points
Current Score
32
Oct 19, 2026
Category Changes
SIGA increased 0.2 points because overall fundamentals improved.
Projected Score
Projected Score
23
Projected Change
-9.5 points
Preliminary comparable-period financial changes suggest decline of approximately 9.5 points. This is a projected estimate, not the official WallStreetScore.
Price vs. Value
Valuation unavailableCurrent Price
$3.15
Model Intrinsic Value
—
Difference
—
Margin of Safety
—
Intrinsic value is not currently available for this stock, so valuation can't be calculated.
Financial Charts
Revenue
Additional Metrics
Operating Cash Flow
Total Debt
Total Assets
Net Margin %
Free includes 3 annual periods plus available TTM; Premium includes up to 10 annual periods. History depends on available company filings. Swipe the table horizontally to see older periods. A dash means unavailable, not zero.
| Line Item | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $53.7M | $94.6M | $138.7M | $139.9M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Cost of Revenue | $24.5M | $29.7M | $31.3M | $17.8M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Gross Profit | $29.2M | $64.9M | $107.4M | $122.1M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Research & Development | $2.70T | $6.5M | $12.3M | $16.4M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| SG&A Expenses | $4.67T | $3.1M | $25.1M | $22.0M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Operating Expenses | $40.3M | $41.2M | $37.4M | $38.5M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| EBITDA | -$4.9M | $31.0M | $76.6M | $88.3M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Operating Income | -$11.1M | $23.7M | $70.0M | $83.6M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Interest Expense | $0.00 | $0.00 | $0.00 | $0.00 | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Income Before Tax | -$5.5M | $30.4M | $76.1M | $87.8M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Income Tax Expense | -$2.7M | $7.1M | $16.9M | $19.7M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Net Income | -$2.8M | $23.3M | $59.2M | $68.1M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Basic EPS | $-0.04 | $0.33 | $0.83 | $0.95 | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Basic Shares | 71.75M | 71.60M | 71.25M | 71.36M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Diluted Shares | 71.88M | 71.60M | 71.77M | 71.68M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
Earnings Summary
Revenue
$41.0M
Estimate unavailable.
Revenue Beat/Miss
Not available (no estimate stored)
EPS
$0.17
Estimate unavailable.
EPS Beat/Miss
Not available (no estimate stored)
Debt Change
-23.0%
Cash Change
-35.6%
Margin Change
-13.3 pp
Debt and cash show percentage changes versus the comparison period; margin shows the change in percentage points (pp). These are company-wide changes, not per-share amounts.
Financial Changes Since Prior Period
What Improved
- Debt reduced
What Weakened
- Margins contracted
- Cash position declined
Potential Score Impact
Positive indicators included debt levels. Pressure indicators included revenue growth, EPS growth, cash levels, net income margin. These factors may support or pressure the Revenue, Management, Financial, and Debt categories; this summary does not claim that the stored scores changed.
Stored Earnings Analysis
Revenue declined 49.5%. EPS declined 65.3%. Cash declined 35.6%. Total debt declined 23.0%. Net income margin declined by 13.3 percentage points.
Earnings-Call Transcript
Earnings-call transcript analysis is not currently available.
These results may influence future scores when the next evaluation is completed.
Insider Activity
Guru / Smart Money
Guru Score
Smart Money
Number of Gurus
Total Guru Value
Avg Portfolio Weight
Largest Holder
Largest Holder %
New Positions
Increased Positions
Reduced Positions
Exited Positions
Net Guru Sentiment
Short Interest
Dividend History
Dividend data is not available yet. Missing data does not mean this company pays no dividend.
Conservative Projected Values
3 Years
$———.——
5 Years
$———.——
10 Years
$———.——
Conservative Projection Rate
——%
Conservative Projected Values — price projections derived from actual 10-year adjusted historical returns, conservatively adjusted and capped at 8% annually. These are distinct from the Outperformance Model Score and WallStreetScore.
Conservative Projected Values
Premium unlocks the 3-year, 5-year, and 10-year conservative projected values with full calculation breakdowns based on actual historical returns.
Start 7-Day Free TrialHistorical Outperformance Record
Premium includes stored forecasts and any available evaluated results. Completed results, win rates and calibrated probabilities are shown only when supported records exist; access does not create historical outcomes.
Start 7-Day Free TrialHistorical Trends
3 historical recordsHistorical Score Chart
3 of 3 records shownWall Street Score
Debt Score
Revenue Score
Asset Score
Capital Score
Management Score
Moat Score
Valuation Score
Buffett Score
Intrinsic Value
Value Reference
Margin of Safety %
Related Companies
Drug Manufacturers - Specialty & GenericRumor Mill · SIGA
Corporate developments & opportunities
No reviewed developments match this filter.
Evidence credibility is not a forecast of stock performance. Rumor Mill is separate from the WSS score.
Related Stock Research
Continue researching this company with related Wall Street Score rankings and investing guides.
Score Alerts
Premium unlocks alerts when a score rises, falls, or reaches your target price.
Start 7-Day Free TrialPortfolio Score
Premium unlocks portfolio scoring, strongest and weakest holdings, and overall margin of safety.
Start 7-Day Free Trial